Roivant Sciences (NASDAQ:ROIV – Get Free Report) had its price objective upped by stock analysts at Jefferies Financial Group from $42.00 to $52.00 in a research note issued on Tuesday, MarketBeat.com reports. The brokerage presently has a “buy” rating on the stock. Jefferies Financial Group’s price objective would indicate a potential upside of 24.63% from […]

Hyperion DeFi (NASDAQ:HYPD – Get Free Report) had its target price raised by equities research analysts at Chardan Capital from $7.30 to $8.45 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Chardan Capital’s target price points to a potential upside of 132.97% […]

Campbell’s (NASDAQ:CPB – Get Free Report) had its target price upped by analysts at UBS Group from $18.00 to $19.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has a “sell” rating on the stock. UBS Group’s price target would indicate a potential downside of 9.86% from […]

Forward Industries (NASDAQ:FWDI – Get Free Report) had its price objective hoisted by stock analysts at B. Riley Financial from $7.00 to $9.00 in a report released on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. B. Riley Financial’s price target points to a potential upside of 36.88% from the […]

KindlyMD (NASDAQ:NAKA – Get Free Report) had its price objective hoisted by stock analysts at B. Riley Financial from $9.00 to $11.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. B. Riley Financial’s target price would suggest a potential upside of 33.66% from […]

Five Below (NASDAQ:FIVE – Get Free Report) had its price target hoisted by Truist Financial from $273.00 to $297.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the specialty retailer’s stock. Truist Financial’s target price suggests a potential upside of 22.51% from the company’s current […]

MiniMed Group (NASDAQ:MMED – Get Free Report) had its target price lifted by investment analysts at Morgan Stanley from $19.00 to $21.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley’s price objective points to a potential downside of 10.81% from the company’s previous […]

NetApp (NASDAQ:NTAP – Get Free Report) had its price objective raised by Bank of America from $180.00 to $206.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “neutral” rating on the data storage provider’s stock. Bank of America‘s target price indicates a potential upside of 10.49% from the […]

Workday (NASDAQ:WDAY – Get Free Report) had its target price lifted by equities research analysts at BMO Capital Markets from $182.00 to $230.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has an “outperform” rating on the software maker’s stock. BMO Capital Markets’ price target indicates a potential upside of 18.82% […]

Duolingo (NASDAQ:DUOL – Get Free Report) had its price objective raised by research analysts at JPMorgan Chase & Co. from $125.00 to $135.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential downside of 4.99% from […]

Revolution Medicines (NASDAQ:RVMD – Get Free Report) had its price objective upped by Truist Financial from $231.00 to $239.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s price target suggests a potential upside of 10.94% from the company’s current price. RVMD has […]

Zscaler (NASDAQ:ZS – Get Free Report) had its target price lifted by analysts at JPMorgan Chase & Co. from $205.00 to $215.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside […]

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) had its price target raised by investment analysts at Truist Financial from $264.00 to $281.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Truist Financial’s price target would suggest a potential […]